Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Blomia tropicalis allergen extract is a biological product derived from the house dust mite *Blomia tropicalis*, which is a primary source of allergens in tropical and subtropical regions. This extract is used for both allergy diagnosis and as a therapeutic agent in allergen immunotherapy (AIT). [5, 14, 18] For diagnosis, it is applied via skin prick tests to identify sensitization in individuals suffering from allergic asthma and rhinitis. [5, 11] As a therapy, the extract is administered, typically via subcutaneous injection, in gradually increasing doses to induce immunological tolerance and reduce the allergic response to the mite. [11] Clinical studies have demonstrated that AIT with *Blomia tropicalis* extract is safe and effective in diminishing symptoms and medication dependency in patients with allergic asthma. [3, 11]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on blomia tropicalis allergen extract.